

**Supplementary Table1. Comparison of disease activity between treatment groups according to underlying disease (per protocol analysis)**

Variable	Total	Continuous-KRG	Placebo-KRG	<i>p</i> value
SjS patients (n = 77) <sup>a)</sup>				
ESSPRI, 0W	60.0 (50.0 to 67.0)	60.0 (50.0 to 67.0)	60.0 (52.2 to 67.0)	0.842
ESSPRI, 12W	50.0 (38.5 to 58.5)	47.0 (37.0 to 60.0)	50.0 (40.8 to 53.0)	0.853
ΔESSPRI (12W)	10.0 (0.0 to 20.0)	7.0 (-3.0 to 20.0)	10.0 (0.8 to 19.2)	0.782
ESSPRI, 24W	47.0 (33.0 to 57.0)	47.0 (37.0 to 60.0)	45.0 (33.0 to 56.0)	0.477
ΔESSPRI (24W)	13.0 (1.5 to 23.5)	10.0 (0.0 to 23.0)	14.0 (6.2 to 24.0)	0.365
RA patients (n = 43) <sup>a)</sup>				
DAS28-ESR, 0W	3.4 (2.6 to 4.1)	3.4 (2.7 to 4.5)	3.3 (2.3 to 4.0)	0.361
DAS28-ESR, 12W	3.4 (2.5 to 3.9)	3.5 (3.1 to 4.0)	3.1 (2.3 to 3.5)	0.033
ΔDAS28-ESR (12W)	0.1 (-0.5 to 0.8)	0.0 (-0.7 to 0.8)	0.1 (-0.4 to 0.6)	0.356
DAS28-ESR, 24W	3.3 (2.4 to 4.0)	3.5 (2.6 to 4.0)	3.0 (2.0 to 4.0)	0.172
ΔDAS28-ESR (24W)	0.3 (-0.5 to 0.8)	0.5 (-0.7 to 0.9)	0.2 (-0.3 to 0.8)	0.925

Values were presented as median (interquartile range).

KRG, Korean Red Ginseng; SjS, Sjogren's syndrome; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score of 28 joints-erythrocyte sedimentation rate.

<sup>a)</sup>ESSPRI was measured for patients with Sjogren's syndrome and both diseases, and DAS28-ESR for RA patients.